No.

Tumor site

Number of patients

Treatment used

Results

Reference

1

Relapsed high-grade gliomas

15

mEHT + alkylating chemotherapy

Tolerable and safe for patients with relapses by high escalation of the dose too.

Wismeth, et al. 2010 [144]

2

Advanced gliomas

12

Chemotherapy, radiotherapy + mEHT

CR = 1, PR = 2, RR = 25%. Median duration of response = 10 m. Median survival = 9 m, 25% survival rate at 1 year.

Fiorentini, Giovanis, et al. 2006 [145]

3

Relapsed malignant gliomas

24

mEHT

Median survival = 19.5 months, 55% survival rate at 1 year, 15% at 2 years.

Fiorentini, Sarti, et al. 2018 [146]

4

Advanced glioblastoma

60

mEHT + immunotherapy

No added toxicity by immunotherapy. Median progression-free survival (PFS) = 13 m. Median follow up 17 m, median OS was not reached. Estimated OS at 30 m was 58%.

Van Gool, et al. 2018 [142]

5

Various brain-gliomas

140

Chemotherapy + radiotherapy + mEHT

OS = 20.4 m. mEHT was safe and well tolerated.

Sahinbas, et al. 2007 [147]

6

High-grade gliomas

179

mEHT + radiotherapy + chemotherapy

Longstanding complete and partial remissions after recurrence in both groups.

Hager, Groenemeyer, et al. 2008 [148]